Broad spectrum of coreceptor usage and rapid disease progression in HIV-1-infected individuals from Central African Republic.
To study the progression of HIV-1 infection and coreceptor usages in Central African Republic, clinical data, plasma viral load, and coreceptor usage of sequential HIV-1 isolates were analyzed in a seroincident prospective cohort (PRIMOCA). Twenty-three HIV-1 infected individuals from the Central African Armed Forces were followed from 1995 to 2000. Viruses were isolated from 17 patients at various time points after seroconversion and their coreceptor usage was examined using GHOST cells expressing CD4 and one of the HIV-1 chemokine coreceptors CCR5, CXCR4, BOB/GPR15, and Bonzo/STRL33/CXCR6. Eleven patients died from AIDS. Eight of them died between 2 and 5 years after seroconversion, after a brief symptomatic stage. Patients who rapidly progressed to AIDS and death displayed the highest viral loads after seroconversion. All isolates obtained soon after seroconversion used CCR5, albeit, in some cases, CXCR4, BOB, or Bonzo were also used. Most isolates remained R5 (59 out of 61 isolates), although viruses using CXCR4 appeared in some cases of progression to AIDS. In several cases, a broad tropism was observed during the course of infection, with a frequent usage of BOB and Bonzo in addition to CCR5. Rapid progression to disease and short survival time among Central African HIV-1 patients appear more frequent than those reported in industrialized countries. Viral coreceptor used was mainly CCR5, but, interestingly, a large part of isolates also used BOB and Bonzo. However, there was no strict correlation between the clinical outcome and extended viral tropism.
Bégaud
Evelyne
E
Institute Pasteur, Bangui, Central Africa Republic.
Feindirongai
Gilbert
G
Versmisse
Pierre
P
Ipero
Julienne
J
Léal
Josiane
J
Germani
Yves
Y
Morvan
Jacques
J
Fleury
Hervé
H
Müller-Trutwin
Michaela
M
Barré-Sinoussi
Françoise
F
Pancino
Gianfranco
G
D000163:Acquired Immunodeficiency Syndrome / Q000401:mortality; D000328:Adult; D000562:Amebiasis / Q000453:epidemiology; D002423:Cause of Death; D002488:Central African Republic / Q000453:epidemiology; D015331:Cohort Studies; D015897:Comorbidity; D018450:Disease Progression; D015658:HIV Infections / Q000453:epidemiology* / Q000821:virology; D006679:HIV Seropositivity; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000453:epidemiology; D008137:Longitudinal Studies; D008297:Male; D008889:Military Personnel; D019713:Receptors, CCR5 / Q000502:physiology; D019718:Receptors, CXCR4 / Q000502:physiology; D000075744:Receptors, CXCR6; D019707:Receptors, Chemokine; D018121:Receptors, Cytokine / Q000502:physiology; D043562:Receptors, G-Protein-Coupled; D015728:Receptors, HIV / Q000502:physiology*; D018000:Receptors, Peptide / Q000502:physiology; D011991:Receptors, Virus; D019562:Viral Load; D014766:Viremia / Q000453:epidemiology* / Q000821:virology
C106330:CXCR6 protein, human; C103539:GPR15 protein, human; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; D000075744:Receptors, CXCR6; D019707:Receptors, Chemokine; D018121:Receptors, Cytokine; D043562:Receptors, G-Protein-Coupled; D015728:Receptors, HIV; D018000:Receptors, Peptide; D011991:Receptors, Virus